SynVaccine
Design and Construction of Viral-based Products
StartupSynVaccine is a Tel Aviv-Yafo-based startup in the Health Tech & Life Sciences sector, established in 2013. Design and Construction of Viral-based Products. The company has raised a total of $1.76M across 2 funding rounds, currently at the Seed stage. SynVaccine was founded by Tamir Tuller and Tuval Ben Yehezkel. Key investors include A2Z Venture Partners, Pix Vine Capital, Yehuda Zisapel (Late), among 6 total investors. The company has 1-10 employees. Core technologies: Biologicals.
With $1.76M in total funding, SynVaccine is a Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: R&D. The company holds 1 patent.
- StageSeed
- ProductR&D
- ModelB2B
- Employees1-10
- HQTel Aviv-Yafo
- DistrictCenter District
- Last Round$1.7M
- A2Z Venture Partners
- Pix Vine Capital
- Yehuda Zisapel (Late)
6 investors total
Tamir TullerCo-Founder & CSO
Tuval Ben YehezkelCo-founder (No longer with the company)
1 article covered by sources including www.globes.co.il.
What does SynVaccine do?
SynVaccine has developed a CAD/CAM platform for designing and fabricating designer viruses for biotechnology. The company utilizes a multidisciplinary approach combining technologies, such as synthetic biology, virology, bio-informatics, engineering, and robotics, to make viruses that can be used to develop new vaccines. SynVaccine's technology enables the design and fabrication of viral genomes using a safety-focused design approach. The resulting viruses have the potential to overcome the limitations of those found in nature or developed through traditional technologies. SynVaccine was founded as part of Rad BioMed, an Israel-based evergreen family fund that invests in early-stage biomedical start-ups, and on the basis of commercialized research from Tel Aviv University and Weizmann Institute of Science led by Professor Tamir Tuller.
How much funding has SynVaccine raised?
SynVaccine has raised $1.76M in total funding across 2 rounds. The company is currently at the Seed stage. Key investors include A2Z Venture Partners, Pix Vine Capital, Yehuda Zisapel (Late).
Who founded SynVaccine?
SynVaccine was founded in 2013 by Tamir Tuller (Co-Founder & CSO), Tuval Ben Yehezkel (Co-founder (No longer with the company)).
What sector is SynVaccine in?
SynVaccine operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Biotechnology.
Where is SynVaccine located?
SynVaccine is based in HaBarzel Street 27, Tel Aviv-Yafo, Israel, Center District.